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OBJECTIVES We aimed to evaluate clinical outcomes among peripheral arterial disease (PAD) patients
following percutaneous coronary intervention (PCI).
BACKGROUND A significant proportion of patients with coronary artery disease undergoing PCI have
concomitant PAD, which may be associated with worse outcomes.
METHODS We performed a pooled analysis of 8 randomized PCI trials. We included multicenter PCI
trials that compared antiplatelet therapies (EPIC, EPILOG, EPISTENT, RAPPORT,
CAPTURE, IMPACT-II, TARGET, and CREDO) and had baseline PAD status
recorded. Multivariable analyses were performed with stepwise logistic regression for 7- and
30-day outcomes and Cox regression for 6-month and 1-year events.
RESULTS In our pooled analysis of 19,867 patients undergoing PCI, 1,602 (8.1%) were previously
diagnosed with PAD. Patients with PAD had higher incidences of 7-day death (1.0% vs.
0.4%; p  0.001) or myocardial infarction (MI) (6.8% vs. 5.6%; p  0.047), 30-day death
(1.7% vs. 0.7%; p  0.001) or MI (7.4% vs. 6.1%; p  0.05), 6-month death (4.2% vs. 1.5%;
p  0.001) or MI (9.1%, vs. 7.7%; p  0.048), and 1-year death (5.0% vs. 2.1%; p  0.001).
There was a trend toward higher major bleeding risk with PAD (4.8% vs. 3.9%; p  0.06).
With multivariable analyses, PAD remains a significant predictor of mortality at 30 days
(hazard ratio [HR] 1.67, 95% confidence interval [CI] 1.03 to 2.70; p  0.039), 6 months
(HR 1.76, 95% CI 1.31 to 2.37; p  0.001), and 1 year (HR 1.46, 95% CI 1.08 to 1.96;
p  0.013).
CONCLUSIONS The presence of PAD is associated with higher rates of post-PCI death and MI, and is an
independent predictor of short- and long-term mortality. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.0671567–72) © 2006 by the American College of Cardiology Foundation
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aeripheral arterial disease (PAD) is prevalent, currently
stimated to affect 8 to 12 million Americans and 27 million
eople in Europe and North America (1). Up to 20% of
mericans 65 years of age suffer from PAD, and this
revalence is estimated to double by 2050 (1,2). Despite its
idespread prevalence, this atherosclerotic manifestation is
requently neglected, with only a quarter of patients under-
oing treatment (3). Peripheral arterial disease often coex-
sts with other manifestations of the systemic atherosclerotic
rocess, including coronary artery disease (CAD) and cere-
rovascular disease (4). In fact, approximately 2 out of 3
atients with PAD have concomitant CAD, and up to 1 out
f 3 elderly patients with CAD have concomitant PAD
5,6). Furthermore, patients with concomitant CAD and
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am, the Netherlands; and the ¶Lindner Center and the Ohio Heart and Vascular
enter at the Christ Hospital, Cincinnati, Ohio.P
Manuscript received October 15, 2005; revised manuscript received February 27,
006, accepted March 21, 2006.AD who undergo coronary revascularization have higher
eriprocedural and long-term complications compared with
hose without PAD (7). This may be due to more extensive
AD or vascular complications related to PAD. Earlier
tudies which evaluated CAD patients undergoing percuta-
eous coronary interventions (PCI) involved either rela-
ively small numbers of PAD patients or only single-center
egistries (8–10). Therefore, we performed a pooled analysis
f 8 large multicenter randomized PCI trials to further
haracterize the impact of PAD on short-term and long-
erm ischemic events following PCI.
ETHODS
he primary reports of the EPIC (Evaluation of c7E3 for
he Prevention of Ischemic Complications), EPILOG
Evaluation of PTCA to Improve Long-Term Outcome by
7E3 GPIIb/IIIa receptor blockade), EPISTENT (Evalu-
tion of IIb/IIIa Platelet Inhibitor for Stenting), CAPTURE
c7E3 Fab Antiplatelet Therapy in Unstable Refractory An-
ina), RAPPORT (ReoPro and Primary PTCAOrganization
nd Randomized Trial), IMPACT-II (Integrilin to Minimize
latelet Aggregation and Coronary Thrombosis II),
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rial), and CREDO (Clopidogrel for the Reduction of Events
uring Observation) trials have been previously reported
11–18). These 8 large multicenter randomized trials were
elected because they studied PCI patients and recorded the
resence of PAD as a baseline characteristic. The EPIC,
PILOG, EPISTENT, CAPTURE, RAPPORT, and
MPACT-II trials randomized patients to a glycoprotein (GP)
Ib/IIIa inhibitor versus placebo. The TARGET study ran-
omized patients to abciximab versus tirofiban, and the
REDO study randomized patients to clopidogrel versus
lacebo. All patients received aspirin and heparin. Baseline
haracteristics and outcome data from these 8 trials were
xtracted from the original trial datasets and pooled for the
resent analysis. End points of death, myocardial infarction
MI), and target vessel revascularization (TVR) were
ooled from studies to assess 7-day, 30-day, and 6-month
vents. One-year events (of which only mortality data were
ollected) were available for EPIC, EPILOG, EPISTENT,
APTURE, TARGET, and CREDO.
efinitions. The presence of PAD was ascertained and
ecorded by site investigators at the time of patient enroll-
ent. However, a specific definition of PAD was not
tipulated by individual studies. Death was defined as
ll-cause mortality. Myocardial infarction was typically de-
ned as creatine kinase (CK) or CK-MB elevation of at
east 3 times the upper limit of normal in hospital or at least
times the upper limit of normal at follow-up or as
evelopment of significant Q waves on electrocardiogram.
Table 1. Baseline Characteristics of Patients U
Presence of PAD
Baseline Characteristics PAD (n
Age (yrs) 65.0 
Body mass index 30.0 
Male 1,111/1,6
Diabetes mellitus 541/1,6
Current smoker or quit within 1 yr 530/1,5
Hypertension 1,088/1,5
History of MI 747/1,5
History of stroke 101/1,5
History of CHF 245/1,5
Baseline CrCL 80.5 
Continuous variables expressed as mean values  standard d
Abbreviations and Acronyms
CAD  coronary artery disease
CI  confidence interval
GPIIb/IIIa  glycoprotein IIb/IIIa
HR  hazard ratio
MI  myocardial infarction
OR  odds ratio
PAD  peripheral arterial disease
PCI  percutaneous coronary intervention
TVR  target vessel revascularizationCHF  congestive heart failure; CrCL  creatinine clearance
disease; PCI  percutaneous coronary intervention.arget vessel revascularization was defined as either percu-
aneous revascularization or bypass surgery to a vessel that
ad been treated during the index procedure. Bleeding
omplications were defined according to the individual
tudies; the majority used the criteria defined by the Throm-
olysis In Myocardial Infarction (TIMI) Study Group (19).
tatistics. Baseline characteristics and outcomes were
tratified by the presence of PAD. Baseline characteristics
ere compared with chi-square test for discrete variables
nd Wilcoxon rank-sum test for continuous variables. Hy-
othesis testing was done using 2-sided tests at the 5%
ignificance level. Survival estimates were computed using
aplan-Meier estimates and compared using the log-rank
est. Multivariable analyses were performed with stepwise
ogistic regression for 7- and 30-day outcomes and stepwise
ox regression for 30-day, 6-month, and 1-year events. The
egression models adjusted for age, body mass index, gen-
er, diabetes mellitus, smoking, hypertension, prior MI,
rior stroke, prior congestive heart failure, and baseline
reatinine clearance. Hazard ratios (HR) are reported with
5% confidence intervals (CI). In a subanalysis including
nly the 6 trials that randomized PCI patients to GPIIb/
IIa inhibitor versus placebo, the outcomes evaluating the
andomized treatment were stratified according to the
resence of PAD. The Breslow-Day test was performed to
nsure homogeneity of the 8 randomized trials (p 0.05 for
ll outcomes assessed). All statistical analyses were per-
ormed with SAS (Version 8; SAS Institute, Cary, North
arolina).
ESULTS
n this pooled analysis of 8 randomized trials, of 19,867
atients who underwent PCI, 1,602 (8.1%) were previously
iagnosed with PAD. The baseline characteristics are de-
cribed in Table 1. Patients with PAD were older, more
requently female, had lower body mass index, more ath-
rosclerotic risk factors (diabetes, hypertension, current
moker), more frequent history of MI, stroke, and conges-
ive heart failure, and lower baseline creatinine clearance.
going PCI Stratified According to the
02) No PAD (n  18,265) p Value
60.4  10.9 0.001
31.6  21.5 0.001
9.4) 13,451/18,265 (73.6) 0.001
3.8) 3,917/18,257 (21.5) 0.001
3.3) 5,265/18,125 (29.0) 0.001
8.1) 10,391/18,219 (57.0) 0.001
6.8) 7,798/18,186 (42.9) 0.002
.3) 340/18,255 (1.9) 0.001
5.3) 1,165/18,228 (6.4) 0.001
94.3  41.8 0.001
n and categorical variables expressed as n/N (%).nder
 1,6
10.0
17.9
02 (6
01 (3
90 (3
97 (6
96 (4
99 (6
98 (1
35.0
eviatio
; MI  myocardial infarction; PAD  peripheral arterial
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October 17, 2006:1567–72 Impact of PAD on PCI Outcomesnadjusted analyses. In the unadjusted analyses, patients
ith PAD had higher mortality at 7-day (1.0 vs. 0.4%; p 
.001), 30-day (1.7% vs. 0.7%; p  0.001 [HR 2.18, 95%
I 1.36 to 3.52; p 0.001]), 6-month (4.2%, vs. 1.5%; p
.001 [HR 2.68, 95% CI 2.01 to 3.59; p  0.001]), and
-year (5.0% vs. 2.1%; p 0.001 [HR 2.25, 95% CI 1.69 to
.01; p  0.001]) follow-ups compared with patients
ithout PAD (Fig. 1). The 1-year Kaplan-Meier curve for
nadjusted mortality is shown in Figure 2 (log-rank chi-
quare  48.1). Patients with PAD also had higher inci-
ences of MI at 7-day (6.8% vs. 5.6%; p  0.047), 30-day
7.4% vs. 6.1%; p  0.05), and 6-month (9.1% vs. 7.7%;
 0.048) follow-ups. There were no significant differences
n TVR between patients with or without PAD at 7-day
3.9% vs. 3.4%, respectively; p  0.28), 30-day (4.9% vs.
.4%; p  0.37), or 6-month (16.0% vs. 14.9%; p  0.22)
ollow-ups. However, PAD was associated with a higher
omposite end point of death, MI, or TVR at 7-day (10.0%
s. 8.0%; p  0.004), 30-day (11.7% vs. 9.5%; p  0.003),
nd 6-month (24.5% vs. 20.5%; p  0.001) follow-ups.
here was a trend toward a higher incidence of major
leeding (4.8% vs. 3.9%; p  0.062) and minor bleeding
vents (8.0% vs. 6.8%; p  0.066) among patients with
AD.
ultivariable analyses. After multivariable analyses ad-
usting for all baseline characteristics, the presence of PAD
emained an independent predictor of mortality but not of
I events. Peripheral arterial disease was a significant
redictor of mortality at 30-day (HR 1.67, 95% CI 1.03 to
.7; p  0.039) (Fig. 3A), 6-month (HR 1.76, 95% CI
.31–2.37; p 0.001) (Fig. 3B), and 1-year (HR 1.46, 95%
I 1.08–1.96; p  0.013) (Fig. 3C) follow-ups. Indepen-
ent predictors of 1-year mortality were history of conges-
ive heart failure, diabetes mellitus, presence of PAD,
ypertension, prior MI, increasing age, and worse creatinine
learance (Table 2). There was no heterogeneity in the
xcess mortality among the trials (p  0.05 for all out-
omes). Peripheral arterial disease was a significant predic-
or of the composite death, MI, or TVR event rate at 6
onths (HR 1.17, 95% CI 1.05 to 1.31; p  0.005).
andomized trials of GPIIb/IIIa inhibitor versus placebo.
n a subanalysis of the 6 randomized PCI trials (n 12,238)
igure 1. Unadjusted analysis comparing 7-day, 30-day, 6-month, and
-year mortality among patients with peripheral arterial disease (PAD)
ersus no PAD.omparing GPIIb/IIIa inhibitor versus placebo (EPIC, pPILOG, EPISTENT, CAPTURE, RAPPORT, and
MPACT-II), we stratified outcomes of randomized treat-
ent according to PAD presence. Among patients with
AD (n  880), the use of GPIIb/IIIa inhibitor was
ssociated with lower composite death, MI, or TVR event
ate at 7 days (9.1% vs. 14.9%; p  0.009) and 30 days
11.0% vs. 15.6%; p  0.05) compared with placebo.
owever, this was no longer significant at 6 months (27.1%
s. 30.2%; p 0.33) (Fig. 4). There appeared to be a higher
isk of major bleeding with the use of GPIIb/IIIa inhibitors
n PAD patients, although this was not statistically signif-
cant (7.1% for GPIIb/IIIa inhibitors vs. 4.6% placebo; p 
.15). The use of GPIIb/IIIa inhibitors during PCI confers
imilar benefit irrespective of the presence of PAD (Fig. 4).
ISCUSSION
he present analysis evaluates the impact of PAD on the
utcomes of patients undergoing PCI. The principal find-
ngs are that PAD was independently associated with higher
ost-PCI mortality at multiple follow-up intervals (30 days,
months, and 1 year). Peripheral arterial disease was
ssociated with a trend toward higher major bleeding
omplications after PCI, particularly with the use of GPIIb/
IIa inhibitors compared with placebo. Furthermore, when
ompared with patients without PAD, patients with PAD
ad similar reductions in death, MI, or TVR event rates at
and 30 days when randomized to GPIIb/IIIa inhibitors
ompared with placebo.
Our data are concordant with recent nonrandomized
tudies evaluating outcomes of PAD patients undergoing
CI (8–10). Chiu et al. (8) performed an analysis of
ARGET (n  4,809), addressing the outcomes of 469
AD patients (10%) undergoing PCI. These patients had
.3 times higher 1-year mortality compared with those
ithout PAD. In a retrospective, single-center Mayo Clinic
CI registry by Singh et al. (9), 18% (1,397 of 7,696) of
atients undergoing PCI had concomitant PAD. These
atients were older than non-PAD patients and had higher
requencies of diabetes, hypertension, smoking, and mul-
igure 2. The 1-year Kaplan-Meier unadjusted mortality curve. PAD 
eripheral arterial disease.
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Impact of PAD on PCI Outcomes October 17, 2006:1567–72ivessel CAD. Peripheral arterial disease patients had higher
n-hospital death, MI, and need for blood transfusion. At a
igure 3. Multivariable analyses evaluating adjusted hazard ratio (HR) m
onths, and (C) 1 year. CI  confidence interval; PAD  peripheral artedian follow-up of 3.1 years, PAD was associated with sigher mortality (HR 1.48; p  0.001) despite adjusting for
aseline variables. Similarly, in another retrospective registry
ty outcomes for individual studies and pooled data at (A) 30 days, (B) 6
isease.ortalitudy by Nikolsky et al. (10), the outcomes of 1,969 PAD
(
P
c
t
o
r
e
r
c
t
r
o
o
i
G
s
f
h
c
a
b
m
v
N
n
t
p
d
o
r
r
p
(
p
D
l
n
S
w
c
u
u
T
i
n
u
i
F
c
r
T
M
P
D
P
H
P
A
B
*
b
d
1571JACC Vol. 48, No. 8, 2006 Saw et al.
October 17, 2006:1567–72 Impact of PAD on PCI Outcomes18.9% of 10,440) patients undergoing PCI were evaluated.
atients with symptomatic PAD had higher in-hospital
omplications, 1-year mortality, MI, and TVR. With mul-
ivariate analysis, PAD remained an independent predictor
f 1-year mortality (OR 1.71; p  0.001).
Our study extends the observations made in earlier
etrospective studies. The data for our pooled analysis is
xtrapolated from the original databases of large multicenter
andomized trials. The data collection (of both baseline
haracteristics and clinical outcomes) in randomized con-
rolled trials is generally more complete compared with
egistry studies. Our study population included an aggregate
f 19,867 CAD patients undergoing PCI, which represents
ne of the largest PCI populations to date. Furthermore, the
nclusion of 6 randomized trials (n  12,238) comparing
PIIb/IIIa inhibitors to placebo enabled a pooled and
tratified subanalysis of the benefit of GPIIb/IIIa inhibitors
or PAD patients, which had not been previously evaluated.
igure 4. Subanalysis of 6 randomized percutaneous coronary intervention
able 2. Independent Predictors of One-Year Mortality With
ultivariable Cox Regression Analysis
Independent Predictors of 1-Yr
Mortality
Hazard Ratio
(95% CI) p Value
rior congestive heart failure 2.52 (1.92–3.30) 0.001
iabetes mellitus 1.51 (1.19–1.91) 0.001
resence of peripheral arterial disease 1.46 (1.08–1.96) 0.013
ypertension 1.34 (1.05–1.72) 0.019
rior myocardial infarction 1.34 (1.08–1.68) 0.009
ge* 1.26 (1.09–1.45) 0.001
aseline creatinine clearance† 0.89 (0.85–0.94) 0.001
Hazard ratio for age is presented for every 10-yr increase in age. †Hazard ratio for
aseline creatinine clearance is presented for every 10-ml/min increase. The remain-
er of the variables were dichotomous.omposite event rates (death, myocardial infarction, or target vessel revasculari
elative risk reduction.There are several potential mechanistic etiologies for the
igher mortality observed in our patient subset with con-
omitant PAD and CAD. This is likely predominantly
ttributed to the more extensive systemic atherosclerotic
urden in this patient population. Such systemic burden
ay culminate in not only cardiovascular, but also cerebro-
ascular complications. Both studies by Rihal et al. (7) and
ikolsky et al. (10) have shown higher prevalence of
eurologic complications (stroke or transient ischemic at-
acks) following PCI in patients with PAD. Furthermore,
atients with PAD undergoing PCI were also more likely to
evelop vascular complications such as retroperitoneal hem-
rrhage, femoral hematoma, limb ischemia, bleeding, and
equirement for blood transfusion (10). In addition, in a
ecent biochemical study by Narins et al. (20), post-MI
atients who have symptomatic intermittent claudication
78 of 1,045 patients) were shown to have enhanced
roinflammatory and procoagulant states. Measurements of
-dimer, fibrinogen, C-reactive protein, and serum amy-
oid A were significantly higher among claudicants versus
onclaudicants.
tudy limitations. There are several limitations associated
ith this study. Despite inclusion of only randomized
ontrolled trials, the data derived from pooled analyses are
sually only hypothesis generating. The definition of PAD
sed in our analysis was not unified in the studies included.
he diagnosis of PAD was ascertained and recorded by site
nvestigators; however, the definitions used at each site were
ot specified in the study protocols. Given the universal
nderdiagnosis of PAD, it is most likely that our study
ncluded higher-risk PAD patients, with symptomatic clau-
comparing glycoprotein (GP) IIb/IIIa inhibitor versus placebo, stratifyingtrials
zation) according to peripheral arterial disease (PAD) presence. RRR 
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Impact of PAD on PCI Outcomes October 17, 2006:1567–72ication or critical limb ischemia or who had undergone
ascular surgery. Nevertheless, our broad inclusion of PAD
atients allows extrapolation of our findings to a more
real-life” PCI population. Although the baseline charac-
eristics of our PAD population were significantly different
rom the non-PAD population (older, higher incidence of
therosclerotic risk factors, worse renal function, prior MI,
troke, and congestive heart failure), multivariable analyses
djusting for these characteristics were performed. Periph-
ral arterial disease remained a significant predictor of
ortality at 30 days, 6 months, and 1 year. Of note, we did
ot evaluate the use of beta-blockers in our PAD population
because this was not universally collected in the studies
ncluded), which may be a confounder for our study, because
laudicants who were not treated with beta-blockers had
-fold mortality excess (20). Data from randomized con-
rolled PCI trials specifically including a PAD population
re necessary to provide definitive conclusions; however,
hey are unlikely to be pursued.
onclusions. The presence of concomitant PAD among
atients undergoing PCI is associated with higher rates of
ost-PCI death and MI and is an independent predictor of
hort- and long-term mortality.
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epartment of Cardiovascular Medicine, Cleveland Clinic Foun-
ation, 9500 Euclid Avenue, Desk F25, Cleveland, Ohio 44195.
-mail: bhattd@ccf.org.
EFERENCES
1. Heart disease and stroke statistics—2004 update. Dallas, TX: Amer-
ican Heart Association, 2003.
2. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial
disease detection, awareness, and treatment in primary care. JAMA
2001;286:1317–24.
3. Becker GJ, McClenny TE, Kovacs ME, Raabe RD, Katzen BT. The
importance of increasing public and physician awareness of peripheral
arterial disease. J Vasc Interv Radiol 2002;13:7–11.
4. Bhatt DL. Peripheral arterial disease in the catheterization laboratory:
an underdetected and undertreated risk factor. Mayo Clin Proc
2004;79:1107–9.
5. Ness J, Aronow WS. Prevalence of coexistence of coronary artery
disease, ischemic stroke, and peripheral arterial disease in olderpersons, mean age 80 years, in an academic hospital-based geriatrics
practice. J Am Geriatr Soc 1999;47:1255–6.
6. Dieter RS, Tomasson J, Gudjonsson T, et al. Lower extremity
peripheral arterial disease in hospitalized patients with coronary artery
disease. Vasc Med 2003;8:233–6.
7. Rihal CS, Sutton-Tyrrell K, Guo P, et al. Increased incidence of
periprocedural complications among patients with peripheral vascular
disease undergoing myocardial revascularization in the bypass angio-
plasty revascularization investigation. Circulation 1999;100:171–7.
8. Chiu JH, Topol EJ, Whitlow PL, et al. Peripheral vascular disease and
one-year mortality following percutaneous coronary revascularization.
Am J Cardiol 2003;92:582–3.
9. Singh M, Lennon R, Darbar D, Gersh B, Holmes D, Rihal C. Effect
of peripheral arterial disease in patients undergoing percutaneous
coronary intervention with intracoronary stents. Mayo Clin Proc
2004;79:1113–8.
0. Nikolsky E, Mehran R, Mintz GS, et al. Impact of symptomatic
peripheral arterial disease on 1-year mortality in patients undergoing
percutaneous coronary interventions. J Endovasc Ther 2004;11:60–70.
1. EPIC Investigators. Use of a monoclonal antibody directed against the
platelet glycoprotein IIb/IIIa receptor in high-risk coronary angio-
plasty. N Engl J Med 1994;330:956–61.
2. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor block-
ade and low dose heparin during percutaneous coronary revasculariza-
tion. N Engl J Med 1997;336:1689–96.
3. EPISTENT Investigators. Randomized placebo-controlled and bal-
loon angioplasty controlled trial to assess safety of coronary stenting
with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:
87–92.
4. CAPTURE Investigators. Randomized placebo-controlled trial of
abciximab before and during coronary intervention in refractory
unstable angina. Lancet 1997;349:1429–35.
5. Brener S, Barr L, Burchenal J, et al. Randomized, placebo-controlled
trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty
for acute myocardial infarction. Circulation 1998;98:734–41.
6. IMPACT-II Investigators. Randomized, placebo-controlled trial
of effect of eptifibatide on complications of percutaneous coronary
intervention: IMPACT-II. Lancet 1997;349:1422–8.
7. Topol E, Moliterno D, Herrmann H, et al. Comparison of two
platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for
the prevention of ischemic events with percutaneous coronary revas-
cularization. N Engl J Med 2001;344:1888–94.
8. Steinhubl S, Berger P, Mann J, et al. Early and sustained dual oral
antiplatelet therapy following percutaneous coronary intervention.
JAMA 2002;288:2411–20.
9. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial
Infarction (TIMI) trial—phase I: hemorrhagic manifestations and
changes in plasma fibrinogen and the fibrinolytic system in patients
treated with recombinant tissue plasminogen activator and streptoki-
nase. J Am Coll Cardiol 1988;11:1–11.
0. Narins CR, Zareba W, Moss AJ, et al. Relationship between inter-
mittent claudication, inflammation, thrombosis, and recurrent cardiac
events among survivors of myocardial infarction. Arch Intern Med
2004;164:440–6.
